Laurion Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Laurion Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-26,655	Closed	-$66.4K	–	715
2023 Q2	$66.4K	Hold	26,655	–	–	﹤0.01%	549
2023 Q1	$71.4K	Sell	26,655 -173,345	-87%	-$833K	﹤0.01%	407
2022 Q4	$1.09M	Buy	+200,000	New	+$1.68M	0.01%	331
2022 Q3	–	Sell	-12,656	Closed	-$63K	–	629
2022 Q2	$63K	Buy	+12,656	New	+$70.1K	﹤0.01%	412
2018 Q4	–	Sell	-110,348	Closed	-$5.77M	–	1483
2018 Q3	$5.77M	Buy	+110,348	New	+$6.02M	0.06%	315
2018 Q2	–	Sell	-34,016	Closed	-$1.26M	–	1640
2018 Q1	$1.26M	Buy	+34,016	New	+$908K	0.01%	764
2017 Q4	–	Sell	-200,000	Closed	-$4.98M	–	1919
2017 Q3	$4.98M	Hold	200,000	–	–	0.02%	513
2017 Q2	$3.49M	Buy	+200,000	New	+$3.5M	0.02%	628

Other funds holding GTHX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Laurion Capital Management's GTHX Position: Q3 2023 in Review

Laurion Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2023, closing a stake of 26,655 shares — an estimated $66.4K sold.

Laurion Capital Management first reported a position in GTHX in Q2 2017 and held it in 8 quarters. The position peaked at $5.77M in Q3 2018. 72 funds tracked by Wall St. Rank hold GTHX as of Q3 2023.

Laurion Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Laurion Capital Management sold 26,655 G1 Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $66.4K.
Laurion Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 8 quarters.
Laurion Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $5.77M in Q3 2018.
72 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.